Astellas Eyes Doubling Market Cap On Core, Focus Assets
Offsetting Xtandi Patent Cliff
Astellas lays out new mid-term strategic plan it sees as overcoming looming major expiries while positioning the firm for growth in new areas and a more than doubling in market cap.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: a pioneering KRAS inhibitor approval; Organon’s CEO on the company’s plans; Astellas’s mid-term ambitions; trial disappointment for Novartis’s Beovu; and Indian plans for a pediatric COVID vaccine.
Trial of high-need gene therapy set to restart following the deaths of several participants and the lifting of a clinical hold imposed by the US FDA last year.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.